Skip to main content
Erschienen in: Reactions Weekly 1/2019

01.08.2019 | Case report

Alteplase/dabigatran-etexilate/idarucizumab

Lack of efficacy following concomitant administration of idarucizumab and alteplase and second stroke due to hyper-coagulative effect of dabigatran-etexilate: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

An 82-year-old woman exhibited lack of efficacy following concomitant administration of idarucizumab and alteplase. It was also determined that the therapy with dabigatran etexilate might have predisposed the woman to a hyper-coagulative effect, which resulted in stroke. Additionally the prothrombotic effect of idarucizumab and the reduced effect of alteplase might also have contributed in the stroke [dosages and routes not stated]. …
Literatur
Zurück zum Zitat Simaan N. First case in israel of intravenous thrombolysis with tissue plasminogen activator (TPA) in acute ischemic stroke after dabigatran reversal with idarucizumab. European Stroke Journal 4 (Suppl. 1): 722, May 2019. Available from: URL: http://doi.org/10.1177/2396987319845581 [abstract] -Israel Simaan N. First case in israel of intravenous thrombolysis with tissue plasminogen activator (TPA) in acute ischemic stroke after dabigatran reversal with idarucizumab. European Stroke Journal 4 (Suppl. 1): 722, May 2019. Available from: URL: http://​doi.​org/​10.​1177/​2396987319845581​ [abstract] -Israel
Metadaten
Titel
Alteplase/dabigatran-etexilate/idarucizumab
Lack of efficacy following concomitant administration of idarucizumab and alteplase and second stroke due to hyper-coagulative effect of dabigatran-etexilate: case report
Publikationsdatum
01.08.2019
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-019-65781-5

Weitere Artikel der Ausgabe 1/2019

Reactions Weekly 1/2019 Zur Ausgabe

Case report

Paliperidone

Case report

Clozapine

Case report

Multiple drugs